Evidence map›Paper›PMID 37608076›Full record

ArticleMolecular biotechnology2024

CircRNA-CIRH1A Promotes the Development of Osteosarcoma by Regulating PI3K/AKT and JAK2/STAT3 Signaling Pathways.

Meng Zhang, Xiang Wang, Jianfeng Zhao, Jizhou Yan, Xiaodan He, Danxia Qin, Fang Liang, Kai Tong, Jianjian Wang

Open access · hybridAbstract read
In one paragraph

Article in Molecular biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Meng ZhangDepartment of Thoracic and Bone-Soft Tissue Surgery, Hubei Cancer Hospital, Tongji Medical College, HuaZhong University of Science and Technology, Wuhan, 430079, China.
Xiang WangDepartment of Thoracic and Bone-Soft Tissue Surgery, Hubei Cancer Hospital, Tongji Medical College, HuaZhong University of Science and Technology, Wuhan, 430079, China.
Jianfeng ZhaoDepartment of Orthopedics, Fuyang Traditional Chinese Medicine Orthopedics Hospital, Hangzhou, 311400, Zhejiang, China.
Jizhou YanDepartment of Orthopedics, Beijing University of Chinese Medicine Affiliated Dongzhimen Hospital, Beijing, 100700, China.
Xiaodan HeDepartment of Orthopedics, Fuyang Traditional Chinese Medicine Orthopedics Hospital, Hangzhou, 311400, Zhejiang, China.
Danxia QinDepartment of Orthopedics, Fuyang Traditional Chinese Medicine Orthopedics Hospital, Hangzhou, 311400, Zhejiang, China.
Fang LiangDepartment of Orthopedics, Fuyang Traditional Chinese Medicine Orthopedics Hospital, Hangzhou, 311400, Zhejiang, China. qitk235@163.com.ORCID http://orcid.org/0000-0001-9938-8823
Kai TongDepartment of Orthopedics, Renmin Hospital of Wuhan University, Wuhan, 430060, China. tongkai0108@163.com.
Jianjian WangDepartment of Thoracic and Bone-Soft Tissue Surgery, Hubei Cancer Hospital, Tongji Medical College, HuaZhong University of Science and Technology, Wuhan, 430079, China. Wangjjchn@163.com.
Hubei Cancer Hospital · CNDongzhimen Hospital Affiliated to Beijing University of Chinese Medicine · CNHangzhou Hospital of Traditional Chinese Medicine · CNWuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Osteogenic sarcoma (OS), one of the mesenchymal tumors with a high degree of malignancy, mainly occurs in the metaphysis of the long bones and around the knee joints in children and adolescents. The poor diagnosis in patients with OS can be attributed to the lack of early clinical symptoms, although the growth of tumor mass gradually results in severe pain and systemic symptoms. The mechanisms underlying the pathogenesis of OS are not fully understood. Thus, identifying early diagnostic biomarkers and novel targets involved in the progression of OS is of critical significance in the management of OS. CircRNA is a class of non-coding RNAs characterized by the close-loop structure and increased stability, which are implicated in the regulation of cell proliferation, differentiation, migration, and apoptosis. Moreover, circRNAs also play significant roles in aging and chronic disorders, such as cancer and cardiovascular diseases. Accordingly, we reported the upregulation of circRNA-CIRH1A in OS tissues and cell lines. Silencing circRNA-CIRH1A in OS cell lines (U2OS, HOS, Saos-2, and MG-63) could inhibit the cell proliferation, invasion, migration, and apoptosis, which was also validated in xenograft tumorigenesis mouse model. We further demonstrated that circRNA-CIRH1A sponged miR-1276, which subsequently disrupted the effect of miR-1276 on PI3K/AKT and JAK2/STAT3 signaling pathways. Together, our study revealed the oncogenic role of circRNA-CIRH1A in OS, and identified miR-1276/ PI3K-AKT and JAK2-STAT3 signaling axis as the key downstream mediators of circRNA-CIRH1A.

Indexed as

Cell ProliferationGene Expression Regulation, NeoplasticJanus Kinase 2OsteosarcomaPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA, CircularSignal TransductionSTAT3 Transcription FactorAnimalsApoptosisBone NeoplasmsCell Line, TumorCell MovementHumansMaleJAK2 protein, humanJanus Kinase 2MicroRNAsPhosphatidylinositol 3-KinasesProto-Oncogene Proteins c-aktRNA, CircularSTAT3 protein, humanSTAT3 Transcription FactorAKTcircRNA-CIRH1AJAK2OsteosarcomaPI3KSTAT3

Identifiers

PMID37608076
PMCPMC11424664
OpenAlexW4386083886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.